-Lactamases hydrolyze -lactam antibiotics, a reaction that destroys their antibacterial activity. These enzymes, of which four classes are known, are the primary cause of resistance to -lactam antibiotics. The class A -lactamases form the largest group. A novel class A -lactamase, named the nonmetallocarbapenamase of class A (NMC-A) -lactamase, has been discovered recently that has a broad substrate profile that included carbapenem antibiotics. This is a serious development, since carbapenems have been relatively immune to the action of these resistance enzymes. Inhibitors for this enzyme are sought. We describe herein that a type of monobactam molecule of our design inactivates the NMC-A -lactamase rapidly, efficiently, and irreversibly. The mechanism of inactivation was investigated by solving the x-ray structure of the inhibited NMC-A enzyme to 1.95 Å resolution. The structure shed light on the nature of the fragmentation of the inhibitor on enzyme acylation and indicated that there are two acylenzyme species that account for enzyme inhibition. Each of these inhibited enzyme species is trapped in a distinct local energy minimum that does not predispose the inhibitor species for deacylation, accounting for the irreversible mode of enzyme inhibition. Molecular dynamics simulations provided evidence in favor of a dynamic motion for the acyl-enzyme species, which samples a considerable conformational space prior to the entrapment of the two stable acyl-enzyme species in the local energy minima. A discussion of the likelihood of such dynamic motion for turnover of substrates during the normal catalytic processes of the enzyme is presented.-Lactamases are the primary cause of resistance to -lactam antibiotics (1). These enzymes hydrolyze the -lactam moiety of -lactam antibiotics, and by so-doing, render them inactive. There are four classes of these enzymes, of which the class A is the largest group (1). The active-site serine in the class A -lactamases undergoes acylation by the substrate and the acyl-enzyme intermediate is subsequently hydrolyzed to give substrate turnover (1, 2). Class A enzymes perform this task with their preferred substrates, penicillins, at the diffusion limit (3). Many of the "parental" -lactamases of class A, such as the TEM-1 -lactamase, have undergone mutations that impart to them an increase in the breadth of their substrate profile (1), as well as the ability to avoid being inhibited by the known clinical inhibitors. This is currently a serious clinical challenge.One new class A -lactamase, designated NMC-A 1 (4), and the highly homologous Sme-1 (5) and IMI-1 (6) -lactamases, enjoy an unusually broad substrate profile, which includes penicillins, cephalosporins, and carbapenems (4, 7). Currently, carbapenem antibiotics such as imipenem are considered antibiotics of last resort, and the advent of enzymes that turn them over efficiently bodes poorly for the prospects of continued clinical utility of these versatile antibacterials.The x-ray structure of the NMC-A enzyme, a...